Kids With Food Allergies
 home   
what's new recipes resources allergy alerts find friends
donate shop KFA allergy buyer's guide support forums
  membership   site map     contact us   about   

Food Allergy Resources

Current Clinical Trial Studies Involving Peanut Allergy

October 2011



National Institutes of Health (NIH)

Peanut Allergy Study - Clinical Trial List

These studies involving peanut allergy are currently registered with the National Institutes of Health (as of October 29, 2011).

Study 1:
Title: Oral Immunotherapy (OIT) for Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Other: Peanut flour | Other: Subjects will receive oral oat flour.
Sponsors: Duke University
Gender: Both
Age Groups: Child
Phases: Phase II
Start Date: June 2009
Completion Date: November 2013
Primary Completion Date: November 2012
Outcome Measures: To treat peanut-allergic subjects with peanut OIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance. | To determine the molecular-level effect that peanut OIT has on the peanut-specific cellular and humoral activity/response in peanut-allergic subjects.
URL: http://ClinicalTrials.gov/show/NCT00815035


Study 2:
Title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity | Food Hypersensitivity|Immediate Hypersensitivity
Interventions: Drug: Peanut powder | Drug: Peanut extract|Drug: Placebo extract|Drug: Placebo powder
Sponsors: Johns Hopkins University
Gender: Both
Age Groups: Child|Adult
Phases: Phase I|Phase II
Start Date: March 2010
Completion Date: January 2013
Primary Completion Date: January 2012
Outcome Measures: The primary endpoint is to determine if sublingual administration of peanut extract and oral administration of peanut powder can induce a 10-fold increase in tolerance as measured by food challenge. | The incidence of all serious adverse events on peanut SLIT and peanut OIT. | To assess any changes in clinical and mechanistic endpoints. | Peanut tolerance, as determined by oral food challenge (OFC) after being off daily SLIT and OIT for 4 weeks.
URL: http://ClinicalTrials.gov/show/NCT01084174


Study 3:
Title: Persistence of Oral Tolerance to Peanut
Recruitment: Enrolling by invitation
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Child
Start Date: May 2011
Completion Date: February 2015
Primary Completion Date: February 2015
Outcome Measures: Proportion of participants with peanut allergy at year 6 in the group who consumed peanut and the group who avoided peanut in the LEAP Study. | Proportion of participants with peanut allergy at year 6 in the group who consumed peanut in the LEAP Study. | Proportion of subjects with allergic sensitization to selected ingested and inhaled allergens, and with seasonal rhino-conjunctivitis, perennial rhinoconjunctivitis, and asthma. | Incidence of adverse events, and nutritional evaluations. | Results of cellular and humoral assessments of immune response related to the development of allergy or tolerance to specific allergens.
URL: http://ClinicalTrials.gov/show/NCT01366846


Study 4:
Title: Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Drug: QGE031|Drug: Placebo
Sponsors: Novartis Pharmaceuticals
Gender: Both
Age Groups: Adult
Phases: Phase II
Start Date: November 2011
Completion Date:
Primary Completion Date: February 2013
Outcome Measures: The increase in the threshold dose of peanut protein that includes objective hypersensitivity reactions after treatment assessed by double-blind, placebo-controlled food challenges (DBPCFC) before and after 16 weeks of treatment. | The percentage of patients that experienced an increase from baseline to the end of treatment period in the threshold dose of at least 2 steps (or 10 fold) increase in peanut dose in the DBPCFC after 16 weeks of treatment. | The mean number of steps improved from baseline threshold dose of peanut protein in the DBPCFC after 16 weeks of treatment. | The shift in the mean cumulative doses in peanut protein in the DBPCFC before exhibiting an objective allergic reaction after 16 weeks of treatment.|From baseline, 8, 15, and 29 days (each a treatment day) and every four weeks thereafter, measure blood level of QGE031 (Pharmacokinetics) | From baseline, 8, 15, and 29 days (each a treatment day) and every four weeks thereafter, measure blood level of total IgE (Pharmacodynamics) | From baseline, 8, 15, and 29 days (each a treatment day) and every four weeks thereafter, measure blood level of free IgE (Pharmacodynamics)
URL: http://ClinicalTrials.gov/show/NCT01451450


Study 5:
Title: Mucosal Immunotherapy for Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut flour | Dietary Supplement: Oat|Other: Peanut flour
Sponsors: Duke University | University of Arkansas
Gender: Both
Age Groups: Child
Start Date: March 2007
Completion Date: December 2012
Primary Completion Date: December 2012
Outcome Measures: An outcome measure will be determined by a comparison of the result of the double blind placebo controlled food challenges (DBPCFC) at the starting point and at the end of the study for each of the subjects. | Other outcome measures will be the changes seen in the pre and post peanut skin tests and the pre and post IgE levels to peanut
URL: http://ClinicalTrials.gov/show/NCT00597675


Study 6:
Title: Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Drug: Peanut Oral Immunotherapy|Drug: Omalizumab
Sponsors: Duke University | Genentech
Gender: Both
Age Groups: Child | Adult | Senior
Phases: Phase I | Phase II
Start Date: July 2009
Completion Date: July 2014
Primary Completion Date: July 2014
Outcome Measures: The percentage of subjects who pass the 20gm peanut flour (~50% peanut protein) oral food challenge following the desensitization phase of the study. | Incidence of side effects during initial escalation and build up phase.
URL: http://ClinicalTrials.gov/show/NCT00932282

Study 7:
Title: Epicutaneous Immunotherapy in Peanut Allergy in Children
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Biological: Epicutaneous Immunotherapy | Biological: placebo of peanut
Sponsors: Assistance Publique - H˘pitaux de Paris | DBV Technologies
Gender: Both
Age Groups: Child
Phases: Phase II
Start Date: August 2010
Completion Date: December 2012
Primary Completion Date: October 2012
Outcome Measures: Proportion of patients able to consume >1000 mg of peanut proteins symptom-free. | Description of the level of Ig. | Proportion of patients able to consume >1000 mg of peanut proteins symptom-free. | Proportion of patients able to consume >1000 mg of peanut proteins symptom-free. | Diameter and safety
URL: http://ClinicalTrials.gov/show/NCT01197053


Study 8:
Title: Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Biological: Whole peanut extract | Biological: Placebo formulation
Sponsors: DBV Technologies
Gender: Both
Age Groups: Child | Adult
Phases: Phase I
Start Date: July 2010
Completion Date: October 2011
Primary Completion Date: September 2011
Outcome Measures: Safety evaluation | Systemic reactions evaluation and treatment; treatment adherence
URL: http://ClinicalTrials.gov/show/NCT01170286


Study 9:
Title: Mucosal Immunotherapy for Peanut Allergy in Young Children
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut and placebo flour | Other: Peanut protein flour
Sponsors: Duke University
Gender: Both
Age Groups: Child
Phases: Phase I | Phase II
Start Date: June 2009
Completion Date: December 2014
Primary Completion Date: June 2014
Outcome Measures: To treat peanut-allergic subjects with PMIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance. | To determine the effect that PMIT has on the peanut-specific cellular and humoral response in peanut-allergic subjects.
URL: http://ClinicalTrials.gov/show/NCT00932828


Study 10:
Title: Promoting Tolerance to Peanut in High-Risk Children
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Allergy | Eczema | Egg Allergy | Food Allergy
Interventions: Dietary Supplement: Age appropriate peanut snack | Behavioral: Peanut avoidance
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN)
Gender: Both
Age Groups: Child
Start Date: December 2006
Completion Date: July 2014
Primary Completion Date: July 2014
Outcome Measures: Proportion of participants with peanut allergy at 60 months of age. | Effect of peanut consumption or avoidance on other allergy outcomes|safety of peanut consumption among study participants. | Immunologic mechanisms by which consumption of a peanut-containing snack may induce tolerance to peanuts
URL: http://ClinicalTrials.gov/show/NCT00329784


Study 11:
Title: Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Hypersensitivity | Immediate Hypersensitivity | Peanut Hypersensitivity
Interventions: Biological: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) | Allertein Therapeutics, LLC | Consortium of Food Allergy Research
Gender: Both
Age Groups: Adult
Phases: Phase I
Start Date: October 2009
Completion Date: September 2011
Primary Completion Date: September 2011
Outcome Measures: Percentage of participants who successfully complete the dosage regimen with no more than mild symptoms related to EMP-123 dosing. | Occurrence of adverse events|Rate of desensitization, as determined by peanut endpoint titration prick test in peanut allergic participants|Change in basophil activation. | Decreased Type 2 helper T cell peanut-induced T-lymphocyte phenotype and increased T-lymphocyte regulatory phenotype|Increase in peanut-specific immunoglobulin (IgG4) and IgA. | Decrease in peanut-specific IgE
URL: http://ClinicalTrials.gov/show/NCT00850668


Study 12:
Title: Immunotherapy for Peanut Allergy
Recruitment: Completed
Study Results: No Results Available
Conditions: Allergy
Interventions: Procedure: Sublingual immunotherapy
Sponsors: Duke University
Gender: Both
Age Groups: Child | Adult
Start Date: April 2006
Completion Date: May 2011
Primary Completion Date: May 2011
Outcome Measures: A negative double-blind placebo controlled food challenge at the completion the two years of the study. | A change in the cytokine level between the baseline and each selected time point during the two years of the study.
URL: http://ClinicalTrials.gov/show/NCT00429429


Study 13:
Title: Peanut Sublingual Immunotherapy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Hypersensitivity | Immediate Hypersensitivity | Peanut Hypersensitivity
Interventions: Drug: Peanut powder | Drug: Placebo for peanut powder
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)|Consortium of Food Allergy Research
Gender: Both
Age Groups: Child | Adult
Phases: Phase I | Phase II
Start Date: December 2007
Completion Date: June 2014
Primary Completion Date: December 2010
Outcome Measures: Percentage of desensitized participants (while on daily SLIT) as measured by the 5 gm OFC or a 10-fold increase in the amount of peanut powder, compared to baseline oral food challenge (OFC)|Percentage of participants who tolerate the buildup stage to the planned maintenance dose of peanut SLIT. | Peanut tolerance, as determined by OFC after being off daily SLIT for 8 weeks including differences in immunologic measures versus desensitized participants. | Incidence of all serious adverse events|Changes in immunologic laboratory values
URL: http://ClinicalTrials.gov/show/NCT00580606


Study 14:
Title: Oral Peanut Immunotherapy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Dietary Supplement: Peanut flour OIT
Sponsors: Massachusetts General Hospital
Gender: Both
Age Groups: Child | Adult
Start Date: March 2011
Completion Date: March 2014
Primary Completion Date: August 2012
Outcome Measures: Tolerance | Desensitization | The frequency of side-effects and their relationship to other variables | A significantly lower frequency of accidental ingestion reactions compared to controls | A longitudinal suppression of end-point skin testing by 2 log dilution. | A longitudinal suppression of peanut-specific basophil activation by 1.5 log dilution | A longitudinal doubling of peanut-specific IgG4 | A longitudinal increase of Ara h 2-specific IgG+ B cells by >1.5 SD
URL: http://ClinicalTrials.gov/show/NCT01324401


Study 15:
Title: Omalizumab in the Treatment of Peanut Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Allergy | Peanut Allergy
Interventions: Drug: omalizumab
Sponsors: Johns Hopkins University | National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Adult
Phases: Phase II
Start Date: July 2009
Completion Date: August 2011
Primary Completion Date: August 2011
Outcome Measures: Proportion of participants who have a four-fold increase in the dose of peanut protein needed to induce positive challenge (with final threshold dose >1000 mg) at the 6 month oral food challenge. | Reduction of peanut-allergen induced basophil histamine release in vitro in subjects treated with omalizumab. | Changes in dose of peanut protein needed to induce a positive challenge at the second oral food challenge compared to baseline. | Changes in skin test reactivity on omalizumab therapy and up to 6 months during drug withdrawal. | Changes in free and total peanut-specific IgE and total IgE as well as the ratio of peanut-specific IgE to total IgE on omalizumab therapy and up to 6 months after drug withdrawal. | Changes in basophil markers CD203c, CD63, CD69/ST2, and basogranulin, as well as tryptase during oral food challenges on omalizumab therapy. | Changes in the indirect effects of serum on basophil histamine release on omalizumab therapy and up to 6 months after drug withdrawal.
URL: http://ClinicalTrials.gov/show/NCT00949078


Study 16:
Title: Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy
Recruitment: Enrolling by invitation
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Other: Peanut flour
Sponsors: University of Texas Southwestern Medical Center
Gender: Both
Age Groups: Child
Start Date: February 2010
Completion Date: January 2018
Primary Completion Date: January 2018
Outcome Measures: We will measure changes in the immune system on a molecular level affected by viral infections in peanut allergic children undergoing peanut OIT. | We will determine if our peanut OIT protocol lowers the risk of anaphylaxis in peanut allergic children.
URL: http://ClinicalTrials.gov/show/NCT01074840


Study 17:
Title: Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity | Food Hypersensitivity | Food Allergy | Peanut Allergy
Interventions: Drug: Liquid peanut extract
Sponsors: Duke University | National Institute of Allergy and Infectious Diseases (NIAID) | National Center for Complementary and Alternative Medicine (NCCAM)
Gender: Both
Age Groups: Child
Phases: Phase I | Phase II
Start Date: June 2011
Completion Date: June 2021
Primary Completion Date: December 2017
Outcome Measures: Percentage of subjects on placebo vs peanut SLIT who pass the 54 month double blind, placebo controlled food challenge to assess tolerance. | Percentage of subjects who demonstrate clinical desensitization by passing the 48 month double-blind, placebo-controlled food challenge. | Induction of clinical tolerance after 48months vs 60 months of peanut SLIT.|The change in immune parameters over time associated with the induction of clinical tolerance versus the failure to achieve clinical tolerance.
URL: http://ClinicalTrials.gov/show/NCT01373242


Study 18:
Title: Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Drug: powdered peanut protein
Sponsors: Duke University
Gender: Both
Age Groups: Adult
Phases: Phase II|Phase III
Start Date: December 2010
Completion Date:
Primary Completion Date: September 2014
Outcome Measures: To treat peanut-allergic subjects with POIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance. | To determine the effect that POIT has on the peanut-specific cellular and humoral response in peanut-allergic subjects.
URL: http://ClinicalTrials.gov/show/NCT01274429


Study 19:
Title: An Observational Study of Childhood Food Allergy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Peanut Hypersensitivity | Egg Hypersensitivity | Milk Hypersensitivity
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)|Consortium of Food Allergy Research
Gender: Both
Age Groups: Child
Start Date: July 2006
Completion Date: July 2016
Primary Completion Date: July 2016
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00356174


Study 20:
Title: Xolair Enhances Oral Desensitization in Peanut Allergic Patients
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Other: omalizumab, oral desensitization
Sponsors: Children's Hospital Boston
Gender: Both
Age Groups: Child | Adult
Phases: Phase I | Phase II
Start Date: February 2011
Completion Date: January 2013
Primary Completion Date: January 2013
Outcome Measures: ability of a patient to tolerate rapid oral peanut desensitization to a dose of 500 mg peanut (cumulative dose, 1,000 mg). | Ability of a patient to tolerate rapid oral peanut desensitization to a dose of 4,000 mg of peanut.
URL: http://ClinicalTrials.gov/show/NCT01290913


Study 21:
Title: A Safety and Efficacy Study of Xolair in Peanut Allergy
Recruitment: Terminated
Study Results: http://clinicalstudyresults.gene.com/q2788g.pdf
Conditions: Allergy
Interventions: Drug: Xolair (omalizumab)
Sponsors: Genentech
Gender: Both
Age Groups: Child | Adult | Senior
Phases: Phase II
Start Date: June 2004
Completion Date:
Last Updated: February 28, 2007
Last Verified: February 2007
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00086606


Study 22:
Title: The Effect of Extrinsic Factors on Food Allergy
Recruitment: Not yet recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Other: Food challenge
Sponsors: Cambridge University Hospitals NHS Foundation Trust|Imperial College London
Gender: Both
Age Groups: Adult
Phases: Phase II
Start Date: February 2012
Completion Date: February 2015
Primary Completion Date: January 2015
Outcome Measures: Minimum amount of peanut protein in milligrams which causes an objective clinical reaction during peanut challenges
URL: http://ClinicalTrials.gov/show/NCT01429896


Study 23:
Title: Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity | Eosinophilia | Peanut Hypersensitivity
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Adult
Start Date: August 2010
Completion Date:
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT01212016


Study 24:
Title: Study of Tolerance to Oral Peanut
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Peanut Allergy
Interventions: Dietary Supplement: Peanut oral immunotherapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust
Gender: Both
Age Groups: Child
Phases: Phase I
Start Date: January 2008
Completion Date: January 2012
Primary Completion Date: January 2012
Outcome Measures: Pass/fail peanut challenge
URL: http://ClinicalTrials.gov/show/NCT01259804


Study 25:
Title: Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Peanut Hypersensitivity
Interventions: Procedure: allergy skin testing | Procedure: venepuncture
Sponsors: Hamilton Health Sciences Corporation | Food Allergy Initiative | AllerGen NCE Inc.
Gender: Both
Age Groups: Child | Adult | Senior
Phases:
Start Date: September 2002
Completion Date:
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00243555


Study 26:
Title: A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
Recruitment: Completed
Study Results: http://clinicalstudyresults.gene.com/q3623g.pdf
Conditions: Peanut Hypersensitivity
Interventions: Drug: omalizumab
Sponsors: Genentech
Gender: Both
Age Groups: Child | Adult | Senior
Phases: Phase II
Start Date: November 2006
Completion Date:
Primary Completion Date: June 2008
Outcome Measures: Serious Adverse Events | Food Allergen Exposure, Assessed on Patient-reported Questionnaire | Food-allergic Reactions As Assessed by the Ewan Scale | Nonserious Food-related Adverse Events (AEs) and Other Nonserious AEs
URL: http://ClinicalTrials.gov/show/NCT00382148


Study 27:
Title: Trichuris Suis Ova in Peanut and Tree Nut Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Food Allergy
Interventions: Drug: Trichuris suis ova (TSO)
Sponsors: Beth Israel Deaconess Medical Center | Food Allergy Initiative
Gender: Both
Age Groups: Adult
Phases: Phase I
Start Date: February 2010
Completion Date: December 2011
Primary Completion Date: December 2011
Outcome Measures: Occurrence of unexpected severe side effects
URL: http://ClinicalTrials.gov/show/NCT01070498


Study 28:
Title: Peanut Oral Immunotherapy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut flour
Sponsors: Duke University | University of Arkansas
Gender: Both
Age Groups: Child
Phases:
Start Date: March 2003
Completion Date: July 2012
Primary Completion Date: July 2012
Outcome Measures: Subject will pass a double blind placebo food challenge (DBPCFC) at the end of the study and a second food challenge 1 month later after being off of peanut for 1 month. | IgE to peanut will decrease below a level of 2
URL: http://ClinicalTrials.gov/show/NCT00598039


Study 29:
Title: Double Blind Peanut Sublingual Immunotherapy
Recruitment: Active, not recruiting
Study Results: No Results Available
Conditions: Food Hypersensitivity
Interventions: Other: Peanut protein | Other: Glycerol saline drops | Other: Blood draw and skin tests
Sponsors: Duke University
Gender: Both
Age Groups: Child
Phases:
Start Date: January 2008
Completion Date: December 2014
Primary Completion Date: December 2014
Outcome Measures: Subject will successfully pass a double blind placebo controlled food challenge at the end of the study after having been off the sublingual immunotherapy for 2 to 4 weeks. | The peanut specific IgE will have decreased from the level at the start of the study.
URL: http://ClinicalTrials.gov/show/NCT00597727


Study 30:
Title: Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Inflammatory Disorder
Interventions:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Gender: Both
Age Groups: Child | Adult | Senior
Phases:
Start Date: August 1996
Completion Date:
Last Updated: April 20, 2011
Last Verified: April 2011
Acronym:
Primary Completion Date:
Outcome Measures:
URL: http://ClinicalTrials.gov/show/NCT00557895


Study 31:
Title: Therapeutic Effect of Chinese Herbal Medicine on Food Allergy
Recruitment: Recruiting
Study Results: No Results Available
Conditions: Food Allergy
Interventions: Drug: FAHF-2 (TM)
Sponsors: Li, Xiu-Min, M.D. | National Center for Complementary and Alternative Medicine (NCCAM)
Gender: Both
Age Groups: Child | Adult
Phases: Phase II
Start Date: December 2007
Completion Date: June 2012
Primary Completion Date: May 2012
Outcome Measures: Safety of FAHF-2 | lab studies
URL: http://ClinicalTrials.gov/show/NCT00602160


Study 32:
Title: Evaluation of Food Hypersensitivity in Children/Adolescents With Functional Dyspepsia
Recruitment: Completed
Study Results: No Results Available
Conditions: Dyspepsia
Interventions: Device: in vitro and in vivo allergy testing
Sponsors: Children's Mercy Hospital Kansas City
Gender: Both
Age Groups: Child
Phases: Phase I
Start Date: June 2006
Completion Date: September 2008
Primary Completion Date: September 2008
Outcome Measures: measure specific IgE, IgG total, IgG subclass 4, skin prick tests and atopy patch tests to milk, egg, soy, corn, peanut and wheat. | Determine T-lymphocytes, eosinophils and mast cell densities on duodenal biopsy samples demonstrating eosinophilia.
URL: http://ClinicalTrials.gov/show/NCT00328679

References:
U.S. National Institutes of Health. (October 29, 2011). Clinical Trials. Retrieved October 29, 2011 from http://www.clinicaltrials.gov/.





Kids With Food Allergies is a nonprofit charity. More than 80% of KFA's financial support comes from donors like you. If KFA has helped you in some way, please make a donation to support our work.

Page last updated 7/29/2012

We improve the day-to-day lives of families raising children with food allergies
and empower them to create a safe and healthy future for their children.

Memberships Support Forums Allergy-Free Recipes Allergy Education Resources Friends Connection
Food Allergy Alerts Donate Shop KFA Allergy Buyer's Guide Contact Us Press | Media

Privacy Policy and Terms of Service
Copyright (c) 2005-2011, Kids With Food Allergies, Inc. All Rights Reserved.
Kids With Food Allergies is a tax exempt charity.